期刊文献+

预定位技术在肿瘤治疗中的应用 被引量:1

Application of technology pretarget in tumor
暂未订购
导出
摘要 预定位技术是在放射免疫治疗基础上发展起来的一种新的肿瘤治疗方法 ,具有与靶抗原亲和力高、毒性低、血清清除快等优点 ,对于实体瘤有很好的疗效。目前的预定位技术主要有生物素和亲合素的预定位模式和双特异性抗体的预定位模式两种。现综述预定位技术的产生、现状及展望。
出处 《国外医学(肿瘤学分册)》 2004年第7期511-513,共3页 Foreign Medical Sciences (Cancer Section)
  • 相关文献

参考文献14

  • 1Juweid ME. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice. J Nucl Med,2002,43(11): 1507-1529.
  • 2Grana C,Chinol M,Robertson C, et al. Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study. Br J Cancer, 2002,86(2) :207-212.
  • 3Axworthy DB,Reno JM,Hylarides MD,et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci USA, 2000,97(4): 1802-1807.
  • 4Breitz HB,Weiden PL, Beaumier PL, et al. Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90Y-DOTA-biotin. J Nucl Med, 2000,41 (1): 131-140.
  • 5Press OW, Corcoran M, Subbiah K, et al. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. Blood, 2001,98(8) :2535-2543.
  • 6Weiden PL, Breitz HB, Press O, et al. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase Ⅰ/Ⅱ study results. Cancer Biother Radiopharm, 2000,15(1) :15-29.
  • 7Zhang M, Zhang Z, Garmestani K, et al. Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effctive in therapy of leukemia/lymphoma xenografts. Proc Natl Acad Sci USA, 2003,100(4): 1891-1895.
  • 8Graves SS, Dearstyne E, Lin Y, et al. Combination therapy with Pretarget CC49 radioimmunotherapy and gemcitabine prolongs tumor doubling time in a murine xenograft model of colon cancer more effectively than either monotherapy. Clin Cancer Res, 2003, 9( 10Pt 1) :3712-3721.
  • 9Wilbur DS,Hamlin DK,Chyan MK,et al. Biotin reagents for antibody pretargeting. 5. Additional studies of biotin conjugate design to provide biotinidase stability. Bioconjug Chem, 2001,12(4) :616-623.
  • 10Goshom S, Sanderson J,Axworthy D, et al. Preclinical evaluation of a humanized NR-LU-10 antibody-streptavidin fusion protein for pretargeted cancer therapy. Cancer Biother Radiopharm, 2001,16(2): 109-123.

同被引文献30

  • 1叶靖,许乙凯.生物素/亲和素系统用于活体分子成像现状[J].国外医学(临床放射学分册),2005,28(4):193-195. 被引量:1
  • 2Goodwin D A,Meares C F,McCall M J,et al. Pretargeted immunoscintigraphy with chimeric antibodies [ J ]. J Nucl Med, 1987,28: 561.
  • 3Boerman O C,Van Schaijk F G, Oyen W J G, et al. Pretargeted radioimmunotherapy of cancer: progress step by step [ J ]. J Nucl Med ,2003,44:400-411.
  • 4Goodwin D A, Meares C F. Pretargeted peptide imaging and therapy [ J ]. Cancer Biother Radiopharm, 1999,14 : 145-152.
  • 5Goldenberg D M. Targeted therapy of cancer with radiolabeled antibodies[J]. J Nucl Med,2002 ,43 :693-713.
  • 6Rosebrough S F, Hartley D F. Biochemical modification of streptavidin and avidin: in vitro and in vivo analysis [J]. J Nucl Med,1996, 37(8) :1380-1384.
  • 7Sharkey R M, Karacay H, Cardillo T M, et al. Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods[ J ]. Clin Cancer Res ,2005,11:7109s-7121 s.
  • 8Hnatowieh D J, Virzi F, Rusekowski M. Investigation of avidin and biotin for imaging applications[ J ]. J Nucl Med, 1987,28 (8) :1294- 1302.
  • 9Zhang M,Zhang Z,Garmestani K,et at. Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xeuografts[ J ]. Proc Natl Acad Sci USA ,2003,100(4) : 1891-1895.
  • 10Graves S S, Dearstyne E, Lin Y, et al. Combination therapy with pretarget CCA9 radioimmunotherapy and gerncitabine prolongs tumor doubling timein amurine xenograftmod elofcolon cancermore effectively than either monotherapy [ J ]. Clin Cancer Res, 2003,9 (10) : 3712-3721.

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部